{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:02Z","timestamp":1792089422459,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001172","name":"Hormel Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2026.201694","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:21:51Z","timestamp":1770970911000},"page":"201694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune shielding of viral vectors via capsid engineering with genetically encoded zwitterionic peptides"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5701-4433","authenticated-orcid":false,"given":"Shao-Chia","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrije","family":"Ratkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janarjan","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Montiel-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay S.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-5664","authenticated-orcid":false,"given":"Michael A.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201694_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib2","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib4","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/1873-3468.13649","article-title":"Interaction of adenovirus with antibodies, complement, and coagulation factors","volume":"593","author":"Allen","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omta.2026.201694_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2023.194","article-title":"Complement System Response to Adeno-Associated Virus Vector Gene Therapy","volume":"35","author":"Kropf","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tibtech.2022.11.006","article-title":"Evading and overcoming AAV neutralization in gene therapy","volume":"41","author":"Earley","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omta.2026.201694_bib7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201694_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201694_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection Risk and Safety of Corticosteroid Use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.omta.2026.201694_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus Entry: From Infection to Immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade","volume":"88","author":"Lam","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ymthe.2006.03.024","article-title":"Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system","volume":"14","author":"Kiang","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201694_bib16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01133-22","article-title":"Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic","volume":"96","author":"Wang","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymthe.2004.09.015","article-title":"Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses","volume":"11","author":"Mok","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"O'Riordan","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","article-title":"Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity","volume":"235","author":"Krutzke","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omta.2026.201694_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/hum.2007.0051","article-title":"Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia","volume":"18","author":"Hofherr","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2016.07.004","article-title":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","volume":"237","author":"Rojas","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omta.2026.201694_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201694_bib25","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201694_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2026.201694_bib27","article-title":"Adenovirus type 34 and HVR1-deleted Adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis risk","author":"Sallard","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.omta.2026.201694_bib28","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1016\/j.biomaterials.2009.07.001","article-title":"Ultra-low fouling peptide surfaces derived from natural amino acids","volume":"30","author":"Chen","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.omta.2026.201694_bib29","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1039\/D3SC01977B","article-title":"Hydration behaviors of nonfouling zwitterionic materials","volume":"14","author":"Sarker","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.omta.2026.201694_bib30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biomaterials.2018.11.012","article-title":"Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery","volume":"192","author":"Banskota","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.omta.2026.201694_bib31","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1021\/acs.biomac.5b01031","article-title":"EKylation: Addition of an Alternating-Charge Peptide Stabilizes Proteins","volume":"16","author":"Liu","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.omta.2026.201694_bib32","doi-asserted-by":"crossref","first-page":"22378","DOI":"10.1002\/anie.202004995","article-title":"Zwitterionic Peptide Cloak Mimics Protein Surfaces for Protein Protection","volume":"59","author":"Yuan","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omta.2026.201694_bib33","doi-asserted-by":"crossref","first-page":"20507","DOI":"10.1021\/jacs.2c09484","article-title":"Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide","volume":"144","author":"Yuan","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omta.2026.201694_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OV.S155946","article-title":"Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer","volume":"7","author":"Nguyen","year":"2018","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.omta.2026.201694_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/pj.2014.46","article-title":"Hemocompatibility of zwitterionic interfaces and membranes","volume":"46","author":"Sin","year":"2014","journal-title":"Polym. J."},{"key":"10.1016\/j.omta.2026.201694_bib36","doi-asserted-by":"crossref","first-page":"23125","DOI":"10.1021\/acs.langmuir.4c02664","article-title":"Zwitterionic Polymers for Biomedical Applications: Antimicrobial and Antifouling Strategies toward Implantable Medical Devices and Drug Delivery","volume":"40","author":"Moayedi","year":"2024","journal-title":"Langmuir"},{"key":"10.1016\/j.omta.2026.201694_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/acs.biomac.9b01191","article-title":"Elucidating Molecular Design Principles for Charge-Alternating Peptides","volume":"21","author":"Smith","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.omta.2026.201694_bib38","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1128\/JVI.00256-06","article-title":"Characterization of a permissive epitope insertion site in adenovirus hexon","volume":"80","author":"McConnell","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1021\/bi9925367","article-title":"High resolution solution structure of the 1.3S subunit of transcarboxylase from Propionibacterium shermanii","volume":"39","author":"Reddy","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.omta.2026.201694_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.virol.2006.01.032","article-title":"Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting","volume":"349","author":"Campos","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.omta.2026.201694_bib41","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201694_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virol.2014.05.030","article-title":"IIIa deleted adenovirus as a single-cycle genome replicating vector","volume":"462\u2013463","author":"Crosby","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.omta.2026.201694_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201694_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.chom.2009.11.006","article-title":"Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit","volume":"6","author":"Bremner","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.omta.2026.201694_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007055","article-title":"Role of kinesins in directed adenovirus transport and cytoplasmic exploration","volume":"14","author":"Zhou","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omta.2026.201694_bib46","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/JVI.02639-14","article-title":"Nuclear import of adenovirus DNA involves direct interaction of hexon with an N-terminal domain of the nucleoporin Nup214","volume":"89","author":"Cassany","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ymthe.2005.08.007","article-title":"Rapid Kupffer cell death after intravenous injection of adenovirus vectors","volume":"13","author":"Manickan","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib48","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating antibodies and macrophages as modulators of adenovirus pharmacology","volume":"87","author":"Khare","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib49","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1128\/JVI.03217-14","article-title":"Impact of Natural IgM Concentration on Gene Therapy with Adenovirus Type 5 Vectors","volume":"89","author":"Qiu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib50","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1128\/JVI.00082-09","article-title":"Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo","volume":"83","author":"Tian","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib51","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/mthe.2000.0120","article-title":"In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice","volume":"2","author":"Bristol","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201694_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","article-title":"Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents","volume":"394","author":"Shashkova","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.omta.2026.201694_bib54","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1038\/s41467-024-54049-9","article-title":"Structure-derived insights from blood factors binding to the surfaces of different adenoviruses","volume":"15","author":"Mudrick","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201694_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201694_bib56","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib57","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1172\/JCI39812","article-title":"Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice","volume":"120","author":"Shiratsuchi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201694_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201694_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010859","article-title":"Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo","volume":"18","author":"Tian","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omta.2026.201694_bib60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/JVI.02889-14","article-title":"Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment","volume":"89","author":"Scherer","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib61","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1128\/JVI.03652-14","article-title":"Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis","volume":"89","author":"Luthra","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201694_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101356","article-title":"FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries","volume":"32","author":"Lu","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201694_bib63","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2020.1747206","article-title":"Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery","volume":"9","author":"Saari","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omta.2026.201694_bib65","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201694_bib66","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1039\/D2SC03519G","article-title":"Motif-based zwitterionic peptides impact their structure and immunogenicity","volume":"13","author":"McMullen","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.omta.2026.201694_bib67","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1089\/hum.2004.15.1125","article-title":"Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination","volume":"15","author":"Campos","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201694_bib68","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.omta.2026.201694_bib69","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omta.2026.201694_bib70","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1038\/ncomms9843","article-title":"Localized reconstruction of subunits from electron cryomicroscopy images of macromolecular complexes","volume":"6","author":"Ilca","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201694_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jsb.2016.04.010","article-title":"Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy","volume":"195","author":"de la Rosa-Trevin","year":"2016","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.omta.2026.201694_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pbiomolbio.2020.05.004","article-title":"Localized reconstruction in Scipion expedites the analysis of symmetry mismatches in cryo-EM data","volume":"160","author":"Abrishami","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.omta.2026.201694_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: Meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.omta.2026.201694_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.omta.2026.201694_bib75","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.omta.2026.201694_bib76","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.omta.2026.201694_bib77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.omta.2026.201694_bib78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1107\/S2059798318006551","article-title":"Real-space refinement in PHENIX for cryo-EM and crystallography","volume":"74","author":"Afonine","year":"2018","journal-title":"Acta Crystallogr. D Struct. Biol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:30:19Z","timestamp":1788553819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X26000297"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201694","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune shielding of viral vectors via capsid engineering with genetically encoded zwitterionic peptides","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201694"}}